Skip to main content
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1994 Nov;57(Suppl):55–56. doi: 10.1136/jnnp.57.suppl.55

Experience with intravenous immunoglobulin in myasthenia gravis: a review.

G Edan 1, F Landgraf 1
PMCID: PMC1016727  PMID: 7964855

Full text

PDF
55

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arsura E. L., Bick A., Brunner N. G., Grob D. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci. 1988 May;295(5):438–443. doi: 10.1097/00000441-198805000-00005. [DOI] [PubMed] [Google Scholar]
  2. Arsura E. L., Bick A., Brunner N. G., Namba T., Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med. 1986 Jul;146(7):1365–1368. [PubMed] [Google Scholar]
  3. Cook L., Howard J. F., Jr, Folds J. D. Immediate effects of intravenous IgG administration on peripheral blood B and T cells and polymorphonuclear cells in patients with myasthenia gravis. J Clin Immunol. 1988 Jan;8(1):23–31. doi: 10.1007/BF00915153. [DOI] [PubMed] [Google Scholar]
  4. Cosi V., Lombardi M., Piccolo G., Erbetta A. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand. 1991 Aug;84(2):81–84. doi: 10.1111/j.1600-0404.1991.tb04912.x. [DOI] [PubMed] [Google Scholar]
  5. Drachman D. B., McIntosh K. R., Reim J., Balcer L. Strategies for treatment of myasthenia gravis. Ann N Y Acad Sci. 1993 Jun 21;681:515–528. doi: 10.1111/j.1749-6632.1993.tb22935.x. [DOI] [PubMed] [Google Scholar]
  6. Dwyer J. M. Manipulating the immune system with immune globulin. N Engl J Med. 1992 Jan 9;326(2):107–116. doi: 10.1056/NEJM199201093260206. [DOI] [PubMed] [Google Scholar]
  7. Ferrero B., Durelli L., Cavallo R., Dutto A., Aimo G., Pecchio F., Bergamasco B. Therapies for exacerbation of myasthenia gravis. The mechanism of action of intravenous high-dose immunoglobulin G. Ann N Y Acad Sci. 1993 Jun 21;681:563–566. doi: 10.1111/j.1749-6632.1993.tb22941.x. [DOI] [PubMed] [Google Scholar]
  8. Gajdos P., Outin H., Elkharrat D., Brunel D., de Rohan-Chabot P., Raphael J. C., Goulon M., Goulon-Goeau C., Morel E. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984 Feb 18;1(8373):406–407. doi: 10.1016/s0140-6736(84)90469-0. [DOI] [PubMed] [Google Scholar]
  9. Meiner Z., Ben-Hur T., River Y., Reches A. Aseptic meningitis as complication of intravenous immunoglobulin therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry. 1993 Jul;56(7):830–831. doi: 10.1136/jnnp.56.7.830-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Pascuzzi R. M., Coslett H. B., Johns T. R. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984 Mar;15(3):291–298. doi: 10.1002/ana.410150316. [DOI] [PubMed] [Google Scholar]
  11. Verma P., Oger J. Treatment of acquired autoimmune myasthenia gravis: a topic review. Can J Neurol Sci. 1992 Aug;19(3):360–375. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES